Pyxis Oncology, Inc. License Agreements
7 Contracts & Agreements
- Amendment No. 4 to License Agreement by and between Pyxis Oncology, Inc. and Biosion USA, Inc, dated May 17, 2023 (Filed With SEC on August 11, 2023)
- Amended and Restated License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated October 6, 2022 (Filed With SEC on November 1, 2022)
- License Agreement, dated March 28, 2022 between the registrant and Biosion USA, Inc (Filed With SEC on May 13, 2022)
- First Amendment to License Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc (Filed With SEC on September 17, 2021)
- Exclusive License Agreement between the University of Chicago and Pyxis Oncology for Cancer Immunotherapy Technology (Filed With SEC on September 17, 2021)
- Amendment No. 1 to License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc (Filed With SEC on September 17, 2021)
- License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc (Filed With SEC on September 17, 2021)
